China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food and Drug Administration (FDA) to initiate a clinical study for its MRANK-106, a dual inhibitor of WEE1 and YES1 kinases. This marks a significant milestone for the company as it expands its innovative oncology pipeline into the global market.
Innovative Drug Profile
MRANK-106, a potentially first-in-class drug candidate, is designed to reduce the hematological toxicity associated with WEE1-selective inhibitors. Preclinical studies have shown strong efficacy in various cancer models, including pancreatic, small cell lung, ovarian, breast, and colorectal cancers. This broad spectrum of activity positions MRANK-106 as a promising therapeutic option for multiple solid tumors.
Clinical Trial Outlook
The FDA clearance allows MindRank to proceed with clinical evaluation of MRANK-106 in patients with solid tumors. The study will assess the safety, tolerability, and preliminary efficacy of the drug, with the goal of establishing a robust clinical profile to support further development.-Fineline Info & Tech
Leave a Reply